MARKET

ACORQ

ACORQ

Acorda Thrpeutcs
OTCPK
0.660
-0.090
-12.00%
Opening 15:44 05/24 EDT
OPEN
0.750
PREV CLOSE
0.750
HIGH
0.780
LOW
0.650
VOLUME
22.10K
TURNOVER
15.22K
52 WEEK HIGH
24.20
52 WEEK LOW
0.295
MARKET CAP
819.78K
P/E (TTM)
-0.0031
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACORQ last week (0513-0517)?
Weekly Report · 4d ago
Financial Report: "ACORDA THERAPEUTICS, INC. - Form 10-Q for the quarterly period ended March 31, 2024
Press release · 05/14 14:20
Weekly Report: what happened at ACORQ last week (0506-0510)?
Weekly Report · 05/13 09:23
Weekly Report: what happened at ACORQ last week (0429-0503)?
Weekly Report · 05/06 09:25
Weekly Report: what happened at ACORQ last week (0422-0426)?
Weekly Report · 04/29 09:27
Weekly Report: what happened at ACORQ last week (0415-0419)?
Weekly Report · 04/22 09:25
Weekly Report: what happened at ACORQ last week (0408-0412)?
Weekly Report · 04/15 09:23
*News On Acorda Therapeutics Inc. (ACOR) Now Under ACORQ
Dow Jones · 04/12 21:08
More
About ACORQ
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Webull offers Acorda Therapeutics Inc stock information, including OTCPK: ACORQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACORQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACORQ stock methods without spending real money on the virtual paper trading platform.